Bicara Therapeutics
- Market cap
- 1.09B
- P/E (TTM)i
- -5.35
- P/Bi
- 2.32
- EPSi
- -2.52
- Div yieldi
- 0.00%
- 52W posi
- 16%
Anonymous reader poll. Unscientific, not investment advice.
Bicara Therapeutics shares were changing hands at 16.42, down 0.85% on the day. At current prices, the business is worth about 1.09B, the #3193 most valuable US-listed company we track. Across 6 analysts the consensus rating is Buy, with an average price target of 36.67 (+123%). Against a 52-week band of 13.70-30.99, the shares are currently 16% of the way up.
✦ StockVane Quant Insights how this is computed
- Not yet in the StockVane Momentum strategy's universe - this name needs price history back to 2021 for a reliable signal and doesn't have it yet (most often because it IPO'd or was spun off more recently). This grade is a preliminary blend of valuation, momentum and analyst data, not a Momentum buy/sell call.
- Valuation sits at the 81% percentile of its own 5-year range.
- Price momentum averages -27.8% across the trailing 3-month/1-year windows.
- Analyst consensus across 6 analysts is Buy.
- Recent price momentum is -27.8% on average (3-month/1-year).
- Main-fund capital flow has been a net inflow over the last 45 sessions.
- Short interest has risen to 16.9% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Price chart
Performance
Key statistics
Price & volume
- Prev close
- 16.56
- Open
- 16.44
- Day range
- 16.25 - 17.11
- Avg price
- 16.61
- Volume
- 915.60K
- Turnover
- 15.21M
- Turnover ratei
- 2.49%
- Volume ratioi
- 1.15
- Amplitudei
- 5.22%
- 52-week rangei
- 13.70 - 30.99
Valuation
- P/Ei
- -6.52
- P/E (TTM)i
- -5.35
- P/Bi
- 2.32
- EPSi
- -2.52
- Book value / shi
- 7.08
- Net profit
- -166.76M
- Net assets
- 468.77M
Share structure
- Market cap
- 1.09B
- Float capi
- 603.64M
- Shares out
- 66.17M
- Float sharesi
- 36.76M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2024-09-13
47.0% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
+2.35M net over the window
Short interest
- Shares short
- 11.19M
- % of floati
- 16.91%
- Days to coveri
- 22.56
- As of
- 2026-09-15
Frequently asked questions
What is the current stock price of Bicara Therapeutics (BCAX)?
Bicara Therapeutics last traded at 16.42. The quote on this page refreshes every few seconds while US markets are open.
What is Bicara Therapeutics's market cap?
About 1.09B.
What is the P/E ratio of Bicara Therapeutics?
The trailing twelve-month P/E is -5.35. The Valuation tab shows it against the stock's own five-year range.
Does Bicara Therapeutics pay a dividend?
Bicara Therapeutics does not currently pay a regular dividend.
Is Bicara Therapeutics a buy according to analysts?
The consensus of 6 analysts is a Buy rating, with an average 12-month price target of 36.67, which implies 123.3% upside from the current price. This is not investment advice.
Quote time 2026-10-08 07:00:14 · For reference only, not investment advice and not tailored to your situation.